Venrock Healthcare Capital Partners II, L.P. 13D and 13G filings for Marinus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:07 pm Sale |
2022-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
Venrock Healthcare Capital Partners II, L.P. | 1,770,705 3.700% |
-1,109,391 (-38.52%) |
Filing |
| 2022-02-14 4:18 pm Purchase |
2021-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
Venrock Healthcare Capital Partners II, L.P. | 2,880,096 7.800% |
291,155 (+11.25%) |
Filing |
| 2021-02-16 4:09 pm Purchase |
2020-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
Venrock Healthcare Capital Partners II, L.P. | 2,588,941 7.300% |
963,231 (+59.25%) |
Filing |